[ad_1]
The CEO of AstraZeneca, Pascal Soriot, indicated this Thursday that the vaccine against covid-19 that the pharmaceutical company develops with the University of Oxford is still it could be available by the end of the year despite the discontinuation of trials.
The manager had a virtual meeting with the media on Thursday after the tests of the last phase were interrupted when one of the volunteers suffered an “unexpected and inexplicable” adverse reaction.
This possible vaccine, considered one of the most advanced developed in the world, was in the final stages of clinical trials before receiving authorization from regulatory bodies to proceed to immunize the population.
Despite this setback, Soriot trusted be able to have a vaccine available before the end of 2020, although it did not specify when the trials will resume.
(Read also: ‘Regrowth phenomena in other countries are associated with agglomeration’)
“I think we can still have a vaccine before the end of this year or early next year,” he said.
Soriot further stressed that discontinuations of clinical trials of this type due to “adverse events” are not unusual.
(Plus: India sets a new world record with 95,735 cases in 24 hours)
“Actually, it is very common and many experts will corroborate it,” said the manager in this regard, while clarifying that “the difference with other vaccine trials is that the rest of the world is not looking at them. They stop, study and they resume them. “
He noted that the manufacturing capacity for global distribution of the vaccine should be ready by early 2021 and that the company wants it to be available to all regions of the world at the same time.
(You may be interested: Covid-19 vaccine will not be massively distributed before 2022 ‘)
EFE
